ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology
暂无分享,去创建一个
I. Roy | E. Stachowiak | M. Stachowiak | I. Roy | E. Bergey | D. Bharali | I. Klejbor | J. Morys | I. Klejbor | E. K. Stachowiak | D. J. Bharali | I. Spodnik | J. Morys | E. J. Bergey | P. N. Prasad | M. K. Stachowiak | P. Prasad | I. Spodnik
[1] S. W. Davies,et al. Transgenic models of Huntington's disease. , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[2] Indrajit Roy,et al. Transfection of tyrosine kinase deleted FGF receptor-1 into rat brain substantia nigra reduces the number of tyrosine hydroxylase expressing neurons and decreases concentration levels of striatal dopamine. , 2005, Brain research. Molecular brain research.
[3] J. B. Martin,et al. Clinical and neuropathologic assessment of severity in Huntington's disease , 1988, Neurology.
[4] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[5] P. Kehrli,et al. Basic fibroblast growth factor (bFGF) injection activates the glial reaction in the injured adult rat brain , 1996, Brain Research.
[6] Tymish Y. Ohulchanskyy,et al. Optical tracking of organically modified silica nanoparticles as DNA carriers: a nonviral, nanomedicine approach for gene delivery. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[7] Paras N. Prasad,et al. Introduction to Biophotonics , 2003 .
[8] C. Ross,et al. Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.
[9] K. Todd,et al. Doxycycline Reduces Cleaved Caspase-3 and Microglial Activation in An Animal Model of Neonatal Hypoxia-Ischemia , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[10] S. W. Davies,et al. Formation of polyglutamine inclusions in non-CNS tissue. , 1999, Human molecular genetics.
[11] E. Stachowiak,et al. Gene transfer into the central nervous system using herpes simplex virus-1 vectors. , 2000, Folia morphologica.
[12] R. Mott,et al. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation , 1997, Nature Genetics.
[13] D. Tagle,et al. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[14] N. Severs,et al. CONNEXIN EXPRESSION IN HUNTINGTON'S DISEASED HUMAN BRAIN , 1998, Cell biology international.
[15] S. Heck,et al. Genetically engineered mouse models for drug discovery: new chemical genetic approaches. , 2004, Current drug discovery technologies.
[16] R H Myers,et al. Decreased Neuronal and Increased Oligodendroglial Densities in Huntington's Disease Caudate Nucleus , 1991, Journal of neuropathology and experimental neurology.
[17] W. Mark Saltzman,et al. Synthetic DNA delivery systems , 2000, Nature Biotechnology.
[18] S. W. Davies,et al. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[19] Srimoyee Ghosh,et al. A Drosophila ortholog of the human MRJ modulates polyglutamine toxicity and aggregation , 2006, Neurobiology of Disease.
[20] P. Mcgeer,et al. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.
[21] S. Davis,et al. Biomedical applications of nanotechnology--implications for drug targeting and gene therapy. , 1997, Trends in biotechnology.
[22] E. Stachowiak,et al. Assessment of viral and non-viral gene transfer into adult rat brains using HSV-1, calcium phosphate and PEI-based methods. , 2005, Folia morphologica.
[23] C. McKerlie. Cause and effect considerations in diagnostic pathology and pathology phenotyping of genetically engineered mice (GEM). , 2006, ILAR journal.
[24] R. Faull,et al. The distribution of progenitor cells in the subependymal layer of the lateral ventricle in the normal and Huntington’s disease human brain , 2005, Neuroscience.
[25] Bin Liu,et al. Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.
[26] G. Bates,et al. Huntingtin and the molecular pathogenesis of Huntington's disease , 2004, EMBO reports.
[27] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .
[28] X. Fang,et al. Control of CREB-binding Protein Signaling by Nuclear Fibroblast Growth Factor Receptor-1 , 2005, Journal of Biological Chemistry.
[29] E. Stachowiak,et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Jergas,et al. Basal ganglia alterations and brain atrophy in Huntington’s disease depicted by transcranial real time sonography , 1999, Journal of neurology, neurosurgery, and psychiatry.
[31] R. Albin,et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.
[32] J. S. Schneider,et al. Astrocytic Responses to the Dopaminergic Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Cat and Mouse Brain , 1988, Journal of neuropathology and experimental neurology.